4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $42.13.

FDMT has been the topic of a number of analyst reports. Leerink Partners reissued an "outperform" rating and issued a $36.00 price target (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Royal Bank of Canada reduced their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating on the stock in a report on Thursday, November 14th. Cantor Fitzgerald downgraded shares of 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, September 23rd. Chardan Capital reissued a "buy" rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Finally, Morgan Stanley initiated coverage on shares of 4D Molecular Therapeutics in a research note on Thursday, November 21st. They issued an "underweight" rating and a $8.00 target price for the company.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ:FDMT traded up $0.53 during midday trading on Friday, hitting $7.35. The company's stock had a trading volume of 373,867 shares, compared to its average volume of 873,860. The stock has a market capitalization of $339.79 million, a price-to-earnings ratio of -2.58 and a beta of 2.74. 4D Molecular Therapeutics has a fifty-two week low of $6.77 and a fifty-two week high of $36.25. The stock's 50 day simple moving average is $8.43 and its 200 day simple moving average is $15.25.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in FDMT. nVerses Capital LLC acquired a new stake in 4D Molecular Therapeutics in the 3rd quarter valued at approximately $40,000. Values First Advisors Inc. bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter worth approximately $57,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of 4D Molecular Therapeutics by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company's stock valued at $108,000 after purchasing an additional 3,922 shares during the last quarter. Proficio Capital Partners LLC bought a new stake in shares of 4D Molecular Therapeutics in the third quarter worth $108,000. Finally, Quest Partners LLC boosted its holdings in 4D Molecular Therapeutics by 17,409.1% during the second quarter. Quest Partners LLC now owns 5,778 shares of the company's stock worth $121,000 after purchasing an additional 5,745 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.